Андрология и генитальная хирургия. 2019; 20: 21-25
Новые подходы к терапии эректильной дисфункции и симптомов со стороны нижних мочевыводящих путей на фоне доброкачественной гиперплазии предстательной железы
https://doi.org/10.17650/2070-9781-2019-20-3-21-25Аннотация
В статье рассматриваются предпосылки использования ингибиторов фосфодиэстеразы-5 в терапии эректильной дисфункции и симптомов со стороны нижних мочевыводящих путей, а также особое значение тадалафила как единственного препарата данной группы, подходящего для ежедневного применения. Обсуждаются фармакодинамика тадалафила и гипотезы о механизме его влияния на ткань предстательной железы. Уделяется особое внимание эффективности и безопасности использования этого препарата у пожилых мужчин, которым весьма часто требуется терапия по поводу доброкачественной гиперплазии предстательной железы с симптомами со стороны нижних мочевывыводящих путей. Упоминается о возможности применения тадалафила в программах пенильной реабилитации мужчин, перенесших радикальную простатэктомию.
Список литературы
1. Rajfer J., Aronson W.J., Bush P.A. et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326(2):90–4. DOI: 10.1056/NEJM199201093260203.
2. Раснер П.И., Пушкарь Д.Ю. Эректильная дисфункция – разные решения одной проблемы, или Размышления на заданную тему. Медицинский совет 2014;(19):64–71.
3. Глыбочко П.В., Чалый М.Е., Епифанова М.В. и др. Применение аутоплазмы, обогащенной тромбоцитарными факторами роста, в лечении эректильной дисфункции. Урология 2015;(1):100–3.
4. Гамидов С.И., Шатылко Т.В., Гасанов Н.Г., Наумов Н.А. Применение тадалафила по требованию при эректильной дисфункции у особых категорий пациентов. Андрология и генитальная хирургия 2018;19(4): 15–20. DOI: 10.17650/2070-97812018-19-4-15-20.
5. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2(3):415–25. DOI: 10.1111/j.1743-6109.2005.20360.x.
6. McVary K.T., Roehrborn C.G., Kaminetsky J.C. et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401–7. DOI: 10.1016/j.juro.2006.11.037.
7. Takeda M., Yokoyama O., Lee S.W. et al. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol 2014;21(7): 670–5. DOI: 10.1111/iju.12410.
8. Блюмберг Б.И., Шатылко Т.В., Твердохлеб С.А. и др. Комбинированная терапия простатит-ассоциированной копулятивной дисфункции. Урология 2014; (6):27–32.
9. Benelli A., Mariani S., Varca V. et al. Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/ chronic pelvic pain syndrome. Ther Adv Urol 2018;10(12):377–81. DOI: 10.1177/1756287218808677.
10. Uckert S., Küthe A., Jonas U., Stief C.G. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166(6):2484–90.
11. Pattanaik S., Kaundal P., Mavuduru R.S. et al. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using tadalafil. Sex Med 2019;7(1):41–7. DOI: 10.1016/j.esxm.2018.11.008.
12. Ngai H.Y., Yuen K.S., Ng C.M. et al. Metabolic syndrome and benign prostatic hyperplasia: an update. Asian J Urol 2017;4(3):164–73. DOI: 10.1016/j.ajur.2017.05.001.
13. Алексеева Т.А., Шария М.А., Гамидов С.И. и др. Взаимосвязь эректильной дисфункции с параметрами ожирения у больных артериальной гипертензией. Терапевтический архив 2018;90(12):84–9.
14. Adolfsson P., Ahlstrand C., Varenhorst E., Svensson S.P. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 2002;51(1):50–8.
15. Fibbi B., Morelli A., Vignozzi L. et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1 Pt 1):59–69. DOI: 10.1111/j.1743-6109.2009.01511.x.
16. Zenzmaier C., Kern J., Sampson N. et al. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-tomyofibroblast trans-differentiation. Endocrinology 2012;153(11):5546–55. DOI: 10.1210/en.2012-1431.
17. Oelke M., Wagg A., Takita Y. et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebocontrolled clinical studies. BJU Int 2017;119(5): 793–803. DOI: 10.1111/bju.13744.
18. Nishizawa O., Yoshida M., Takeda M. et al. Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. Int J Urol 2015;22(4):378–84. DOI: 10.1111/iju.12699.
19. Jansen P.A., Brouwers J.R. Clinical pharmacology in old persons. Scientifica (Cairo) 2012;2012:723678. DOI: 10.6064/2012/723678.
20. Oelke M., Becher K., Castro-Diaz D. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015;44(5):745–55. DOI: 10.1093/ageing/afv077.
21. Vlachopoulos C., Oelke M., Maggi M. et al. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract 2015;69(12):1496–507. DOI: 10.1111/ijcp.12722.
22. Wagg A. The cognitive burden of anticholinerigics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev 2012;7:42–9.
23. Попков В.М., Шатылко Т.В., Фомкин Р.Н. Прогнозирование результата патогистологического исследования простаты с помощью искусственной нейронной сети. Саратовский научно-медицинский журнал 2014;10(2):328–32.
24. Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М. и др. Роль водоструйной диссекции в улучшении эректильной функции и удержания мочи после нервосберегающей простатэктомии. Урология 2017;(1):43–9.
25. Велиев Е.И., Ванин А.Ф., Котов С.В., Шишло В.К. Современные аспекты патофизиологии и профилактики эректильной дисфункции и кавернозного фиброза после радикальной простатэктомии. Урология 2009;(2):46–51.
26. Montorsi F., Oelke M., Henneges C. et al. Exploratory decision-tree modeling of data from the randomized REACTT trial of tadalafil versus placebo to predict recovery of erectile function after bilateral nerve-sparing radical prostatectomy. Eur Urol 2016;70(3):529–37. DOI: 10.1016/j.eururo.2016.02.036.
Andrology and Genital Surgery. 2019; 20: 21-25
New approaches to management of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia
https://doi.org/10.17650/2070-9781-2019-20-3-21-25Abstract
This paper addresses the background of phosphodiesterase-5 inhibitors use in erectile dysfunction and lower urinary tract symptoms, as well as a special position which is held by tadalafil as an only drug from its class suitable for daily intake. Tadalafil pharmacodynamics and hypotheses concerning its mechanism of action on prostatic tissue are discussed. Special attention is paid to drug»s efficacy and safety in elderly men, who often require therapy for benign prostatic hyperplasia with lower urinary tract symptoms. It is mentioned that tadalafil may be used in penile rehabilitation programs in men who underwent radical prostatectomy.
References
1. Rajfer J., Aronson W.J., Bush P.A. et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326(2):90–4. DOI: 10.1056/NEJM199201093260203.
2. Rasner P.I., Pushkar' D.Yu. Erektil'naya disfunktsiya – raznye resheniya odnoi problemy, ili Razmyshleniya na zadannuyu temu. Meditsinskii sovet 2014;(19):64–71.
3. Glybochko P.V., Chalyi M.E., Epifanova M.V. i dr. Primenenie autoplazmy, obogashchennoi trombotsitarnymi faktorami rosta, v lechenii erektil'noi disfunktsii. Urologiya 2015;(1):100–3.
4. Gamidov S.I., Shatylko T.V., Gasanov N.G., Naumov N.A. Primenenie tadalafila po trebovaniyu pri erektil'noi disfunktsii u osobykh kategorii patsientov. Andrologiya i genital'naya khirurgiya 2018;19(4): 15–20. DOI: 10.17650/2070-97812018-19-4-15-20.
5. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2(3):415–25. DOI: 10.1111/j.1743-6109.2005.20360.x.
6. McVary K.T., Roehrborn C.G., Kaminetsky J.C. et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401–7. DOI: 10.1016/j.juro.2006.11.037.
7. Takeda M., Yokoyama O., Lee S.W. et al. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol 2014;21(7): 670–5. DOI: 10.1111/iju.12410.
8. Blyumberg B.I., Shatylko T.V., Tverdokhleb S.A. i dr. Kombinirovannaya terapiya prostatit-assotsiirovannoi kopulyativnoi disfunktsii. Urologiya 2014; (6):27–32.
9. Benelli A., Mariani S., Varca V. et al. Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/ chronic pelvic pain syndrome. Ther Adv Urol 2018;10(12):377–81. DOI: 10.1177/1756287218808677.
10. Uckert S., Küthe A., Jonas U., Stief C.G. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166(6):2484–90.
11. Pattanaik S., Kaundal P., Mavuduru R.S. et al. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using tadalafil. Sex Med 2019;7(1):41–7. DOI: 10.1016/j.esxm.2018.11.008.
12. Ngai H.Y., Yuen K.S., Ng C.M. et al. Metabolic syndrome and benign prostatic hyperplasia: an update. Asian J Urol 2017;4(3):164–73. DOI: 10.1016/j.ajur.2017.05.001.
13. Alekseeva T.A., Shariya M.A., Gamidov S.I. i dr. Vzaimosvyaz' erektil'noi disfunktsii s parametrami ozhireniya u bol'nykh arterial'noi gipertenziei. Terapevticheskii arkhiv 2018;90(12):84–9.
14. Adolfsson P., Ahlstrand C., Varenhorst E., Svensson S.P. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 2002;51(1):50–8.
15. Fibbi B., Morelli A., Vignozzi L. et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1 Pt 1):59–69. DOI: 10.1111/j.1743-6109.2009.01511.x.
16. Zenzmaier C., Kern J., Sampson N. et al. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-tomyofibroblast trans-differentiation. Endocrinology 2012;153(11):5546–55. DOI: 10.1210/en.2012-1431.
17. Oelke M., Wagg A., Takita Y. et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebocontrolled clinical studies. BJU Int 2017;119(5): 793–803. DOI: 10.1111/bju.13744.
18. Nishizawa O., Yoshida M., Takeda M. et al. Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. Int J Urol 2015;22(4):378–84. DOI: 10.1111/iju.12699.
19. Jansen P.A., Brouwers J.R. Clinical pharmacology in old persons. Scientifica (Cairo) 2012;2012:723678. DOI: 10.6064/2012/723678.
20. Oelke M., Becher K., Castro-Diaz D. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015;44(5):745–55. DOI: 10.1093/ageing/afv077.
21. Vlachopoulos C., Oelke M., Maggi M. et al. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract 2015;69(12):1496–507. DOI: 10.1111/ijcp.12722.
22. Wagg A. The cognitive burden of anticholinerigics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev 2012;7:42–9.
23. Popkov V.M., Shatylko T.V., Fomkin R.N. Prognozirovanie rezul'tata patogistologicheskogo issledovaniya prostaty s pomoshch'yu iskusstvennoi neironnoi seti. Saratovskii nauchno-meditsinskii zhurnal 2014;10(2):328–32.
24. Glybochko P.V., Alyaev Yu.G., Rapoport L.M. i dr. Rol' vodostruinoi dissektsii v uluchshenii erektil'noi funktsii i uderzhaniya mochi posle nervosberegayushchei prostatektomii. Urologiya 2017;(1):43–9.
25. Veliev E.I., Vanin A.F., Kotov S.V., Shishlo V.K. Sovremennye aspekty patofiziologii i profilaktiki erektil'noi disfunktsii i kavernoznogo fibroza posle radikal'noi prostatektomii. Urologiya 2009;(2):46–51.
26. Montorsi F., Oelke M., Henneges C. et al. Exploratory decision-tree modeling of data from the randomized REACTT trial of tadalafil versus placebo to predict recovery of erectile function after bilateral nerve-sparing radical prostatectomy. Eur Urol 2016;70(3):529–37. DOI: 10.1016/j.eururo.2016.02.036.
